Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Virology

• Publication date

  2003-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.77.20.11244-11259.2003PMID 14512572PMCID PMC224963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein

  2002cited by this paper
• Oligomeric Structure of the Human Immunodeficiency Virus Type 1 Envelope Protein on the Virion Surface

  2002cited by this paper
• Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus

  2002cited by this paper
• Addition of a Single gp120 Glycan Confers Increased Binding to Dendritic Cell-Specific ICAM-3-Grabbing Nonintegrin and Neutralization Escape to Human Immunodeficiency Virus Type 1

  2002cited by this paper
• Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1

  2002cited by this paper
• Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin

  2002cited by this paper
• Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins

  2002cited by this paper
• Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization

  2002cited by this paper
• A Replication-Competent, Neutralization-Sensitive Variant of Simian Immunodeficiency Virus Lacking 100 Amino Acids of Envelope

  2002influential reference
• Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development

  2001cited by this paper
• Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers

  2001cited by this paper
• DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques.

  2001cited by this paper
• DNA Vaccination with the Human Immunodeficiency Virus Type 1 SF162ΔV2 Envelope Elicits Immune Responses That Offer Partial Protection from Simian/Human Immunodeficiency Virus Infection to CD8+ T-Cell-Depleted Rhesus Macaques

  2001cited by this paper
• gp120: Biologic aspects of structural features.

  2001cited by this paper
• The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region

  2001cited by this paper
• V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies

  2000cited by this paper
• Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 Isolates

  2000cited by this paper
• Increased Expression and Immunogenicity of Sequence-Modified Human Immunodeficiency Virus Type 1 gag Gene

  2000cited by this paper
• Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution

  2000cited by this paper
• Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?

  2000cited by this paper
• A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure

  2000cited by this paper
• Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits

  2000cited by this paper
• Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins

  2000cited by this paper
• The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors

  2000influential reference
• Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation

  1999cited by this paper
• Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.

  1999cited by this paper
• Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

  1999cited by this paper
• The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

  1999cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• Changes in the Extracellular Envelope Glycoprotein of Variants That Evolve during the Course of Simian Immunodeficiency Virus SIVMne Infection Affect Neutralizing Antibody Recognition, Syncytium Formation, and Macrophage Tropism but Not Replication, Cytopathicity, or CCR-5 Coreceptor Recognition

  1998cited by this paper
• The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

  1998cited by this paper
• The antigenic structure of the HIV gp120 envelope glycoprotein

  1998cited by this paper
• A role for carbohydrates in immune evasion in AIDS

  1998influential reference
• Interactions of Polyclonal and Monoclonal Anti-Glycoprotein 120 Antibodies with Oligomeric Glycoprotein 120-Glycoprotein 41 Complexes of a Primary HIV Type 1 Isolate: Relationship to Neutralization

  1998cited by this paper
• An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades

  1998cited by this paper
• Stabilization of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers by Disulfide Bonds Introduced into the gp41 Glycoprotein Ectodomain

  1998cited by this paper
• Effect of Major Deletions in the V1 and V2 Loops of a Macrophage-Tropic HIV Type 1 Isolate on Viral Envelope Structure, Cell Entry, and Replication

  1998cited by this paper
• Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein

  1997influential reference
• Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160

  1997cited by this paper
• Atomic structure of the ectodomain from HIV-1 gp41

  1997cited by this paper
• Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

  1997cited by this paper
• The antibody response in HIV-1 infection.

  1997cited by this paper
• Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

  1997cited by this paper
• Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions.

  1996cited by this paper
• Codon usage limitation in the expression of HIV-1 envelope glycoprotein.

  1996cited by this paper
• Negative-Stain Immunoelectron-Microscopic Analysis of Small Macromolecules of Immunologic Significance

  1996cited by this paper
• Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.

  1996cited by this paper
• Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions

  1996cited by this paper
• Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cited by this paper
• Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein

  1996cited by this paper
• Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer.

  1996influential reference
• HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.

  1995cited by this paper
• Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.

  1995cited by this paper
• Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120

  1995cited by this paper
• Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding

  1995cited by this paper
• Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

  1995cited by this paper
• Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.

  1995cited by this paper
• Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies

  1994cited by this paper
• Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1

  1994cited by this paper
• Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities

  1994cited by this paper
• Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

  1994influential reference
• HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.

  1994cited by this paper
• An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.

  1994influential reference
• Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding

  1993cited by this paper
• Mutational Analysis of the Assembly Domain of the HIV-1 Envelope Glycoprotein

  1993cited by this paper
• Nonaffinity Purification of Recombinant gp120 for Use in AIDS Vaccine Development

  1993cited by this paper
• Carbohydrates of human immunodeficiency virus.

  1992cited by this paper
• Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

  1992cited by this paper
• Practical on-line determination of biopolymer molecular weights by high-performance liquid chromatography with classical light-scattering detection

  1992cited by this paper
• Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques

  1992cited by this paper
• Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.

  1991cited by this paper
• Importance of conformation on the neutralizing antibody response to HIV-1 gp120.

  1991cited by this paper
• Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.

  1991cited by this paper
• Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses

  1991cited by this paper
• Importance of conformation on the neutralizing antibody response to HIV-1 gp120.

  1991cited by this paper
• Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS

  1991cited by this paper
• Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor: structural enzymatic analysis.

  1990cited by this paper
• Specificity and inhibitory activity of antibodies to Plasmodium falciparum aldolase.

  1990cited by this paper
• Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

  1990cited by this paper
• Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

  1990cited by this paper
• Model for intracellular folding of the human immunodeficiency virus type 1 gp120

  1989cited by this paper
• Immunoelectron microscopy of idiotype-anti-idiotype complexes.

  1989cited by this paper
• Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein.

  1989cited by this paper
• Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis

  1989cited by this paper
• Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120.

  1988cited by this paper
• Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay

  1988cited by this paper
• Conformational studies of bovine alkaline phosphatase in hydrophobic interaction and size-exclusion chromatography with linear diode array and low-angle laser light scattering detection.

  1988cited by this paper
• Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells.

  1987cited by this paper
• Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

  1987cited by this paper
• Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae.

  1987cited by this paper
• Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.

  1986cited by this paper
• The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

  1984cited by this paper
• T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV

  1984cited by this paper
• Determination of molecular weight of membrane proteins by the use of low-angle laser light scattering combined with high-performance gel chromatography in the presence of a non-ionic surfactant.

  1983cited by this paper
• Rapid characterization of protein molecular weights and hydrodynamic structures by quasielastic laser‐light scattering

  1976cited by this paper
• Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140

  year unknowncited by this paper

• Immune perturbation following SHIV infection is greater in newborn macaques than in infants

  2024cites this paper
• Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates

  2024cites this paper
• Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques

  2021cites this paper
• Surface-Functionalized Silica-Coated Calcium Phosphate Nanoparticles Efficiently Deliver DNA-Based HIV-1 Trimeric Envelope Vaccines against HIV-1.

  2021cites this paper
• Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques

  2021cites this paper
• Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge

  2021cites this paper
• Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity

  2020cites this paper
• Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus

  2019cites this paper
• Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells

  2019cites this paper
• Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

  2019cites this paper
• Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV

  2019cites this paper
• Stabilité et fonctionnalité des glycoprotéines de l’enveloppe du VIH-1 recombinant CRF01_AE : rôle de l’histidine en position 375

  2017cites this paper
• Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques

  2017cites this paper
• VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties

  2016cites this paper
• Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers

  2015cites this paper
• Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein

  2015cites this paper
• A recombinant canine distemper virus expressing a modified rabies virus glycoprotein induces immune responses in mice

  2015cites this paper
• A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene

  2015cites this paper
• Protein aggregation in foam fractionation of bovine serum albumin: Effect of protein concentration

  2015cites this paper
• Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies

  2014cites this paper
• Neutralizing Antibodies in Rabbits HIV-Infected Subjects Stimulate Multiclade Neutralization Breadth Developed in Two Envelope Variants Circulating as Initial

  2014cites this paper
• Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclade Neutralizing Antibodies in Rabbits

  2014cites this paper
• Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops

  2014cites this paper
• Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

  2014cites this paper
• Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy

  2014cites this paper
• 51 – Human immunodeficiency virus vaccines

  2013cites this paper
• Stabilizing Exposure of Conserved Epitopes by Structure Guided Insertion of Disulfide Bond in HIV-1 Envelope Glycoprotein

  2013cites this paper
• A Modern Biopharmaceutical to Treat AIDS – Challenges in Designing HIV Env Immunogens for Developing a Vaccine

  2013cites this paper
• HIV‐1 neutralizing antibodies: understanding nature's pathways

  2013cites this paper
• Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector

  2013cites this paper
• A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies

  2013cites this paper
• Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers

  2013cites this paper
• Ligand-induced structural changes in HIV-1 envelope glycoprotein

  2013cites this paper
• Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ

  2013cites this paper
• Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

  2012cites this paper
• HIV vaccine design based on in vivo evolution of quasispecies envelope proteins

  2012cites this paper
• Elicitation of Neutralizing Antibodies Directed against CD4-Induced Epitope(s) Using a CD4 Mimetic Cross-Linked to a HIV-1 Envelope Glycoprotein

  2012cites this paper
• HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.

  2012cites this paper
• Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

  2012cites this paper
• Progress on the Induction of Neutralizing Antibodies Against HIV Type 1 (HIV-1)

  2012cites this paper
• B cell responses against the HIV-1 envelope glycoproteins

  2012cites this paper
• The design and development of an HIV-1 vaccine to elicit a broadly neutralising antibody response

  2012cites this paper
• HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies

  2012cites this paper
• Structural Characteristics Predict the Stability of HIV

  2011cites this paper
• A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

  2011influential citation
• Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies

  2011cites this paper
• A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells

  2011cites this paper
• Stabilization of HIV-1 Envelope in the CD4-bound Conformation through Specific Cross-linking of a CD4 Mimetic*

  2011cites this paper
• Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 ΔCFI shows variability in the V1 and V2 regions.

  2011cites this paper
• Sequential Immunization with a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the In Vivo Development of Neutralizing Antibodies

  2011cites this paper
• Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site*

  2011cites this paper
• Engineering, Expression, Purification, and Characterization of Stable Clade A/B Recombinant Soluble Heterotrimeric gp140 Proteins

  2011cites this paper
• Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding

  2011cites this paper
• Binding Interactions between Soluble HIV Envelope Glycoproteins and Quaternary-Structure-Specific Monoclonal Antibodies PG9 and PG16

  2011cites this paper
• A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

  2011cites this paper
• Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.

  2011cites this paper
• DNA vaccines: an historical perspective and view to the future

  2011cites this paper
• Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens

  2011cites this paper
• Synthetic antibodies targeting HIV-1 infectivity

  2011cites this paper
• Designing Immunogens for Vaccine Development in Reference to HIV

  2011cites this paper
• Expression and Purification of Recombinant Proteins for Vaccine Applications

  2011cites this paper
• Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response.

  2011cites this paper
• Emerging studies of human HIV-specific antibody repertoires.

  2010cites this paper
• Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

  2010cites this paper
• Stabilized HIV-1 Envelope Glycoprotein Trimers Lacking the V1V2 Domain, Obtained by Virus Evolution*

  2010cites this paper
• Alterations in the Immunogenic Properties of Soluble Trimeric Human Immunodeficiency Virus Type 1 Envelope Proteins Induced by Deletion or Heterologous Substitutions of the V1 Loop

  2010cites this paper
• Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant

  2010cites this paper
• The role of antibodies in HIV vaccines.

  2010cites this paper
• ADAPTIVE CHANGES IN HIV-1 SUBTYPE C PROTEINS DURING EARLY INFECTION AND THEIR EFFECT ON DISEASE PROGRESSION

  2010cites this paper
• A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization.

  2010cites this paper
• Following Immunization Recognizing Distinct Structural Elements Glycoprotein-Specific B Cell Subsets Selective Expansion of HIV-1 Envelope

  2009cites this paper
• HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development

  2009cites this paper
• Immunogenicity of HIV-1 envelope glycoprotein oligomers

  2009cites this paper
• Selective Expansion of HIV-1 Envelope Glycoprotein-Specific B Cell Subsets Recognizing Distinct Structural Elements Following Immunization1

  2009cites this paper
• Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS.

  2009cites this paper
• Comparative Immunogenicity of Subtype A Human Immunodeficiency Virus Type 1 Envelope Exhibiting Differential Exposure of Conserved Neutralization Epitopes

  2009cites this paper
• Broadly Reactive Monoclonal Antibodies to Multiple HIV-1 Subtype and SIVcpz Envelope Glycoproteins

  2009cites this paper
• [Novel vaccines. Vaccinations in the near and distant future].

  2009cites this paper
• Influence of Novel CD4 Binding-Defective HIV-1 Envelope Glycoprotein Immunogens on Neutralizing Antibody and T-Cell Responses in Nonhuman Primates

  2009cites this paper
• Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection.

  2009cites this paper
• Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

  2009cites this paper
• Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

  2009cites this paper
• Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

  2008cites this paper
• Dynamics of acute and memory mucosal and systemic immune responses against HIV‐1 envelope following immunizations through single or combinations of mucosal and systemic routes

  2008cites this paper
• Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells.

  2008cites this paper
• Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein (cid:1) †

  2008cites this paper
• Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses

  2008cites this paper
• Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.

  2008cites this paper
• haracterization of immune responses elicited in ice by intranasal co-immunization with HIV-1 Tat , p 140 V 2 Env and / or SIV Gag proteins and the ontoxicogenic heat-labile Escherichia coli nterotoxin

  2008cites this paper
• A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.

  2008cites this paper
• Focused Dampening of Antibody Response to the Immunodominant Variable Loops by Engineered Soluble gp140

  2008cites this paper
• Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.

  2008cites this paper
• HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.

  2008cites this paper
• Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution

  2008cites this paper
• Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.

  2008cites this paper
• A comparison of anionic nanoparticles and microparticles as vaccine delivery systems

  2008cites this paper
• Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein

  2008cites this paper
• Challenges in designing HIV env immunogens for developing a vaccine

  2008cites this paper
• B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4

  2008cites this paper
• Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

  2008cites this paper